uniQure N.V. said the FDA is reviewing its treatment for Huntington's disease.

Nov 2, 2026, 7:19 AM ETTrialRead the original at SEC EDGAR

Good for QURE

FDA acceptance and Priority Review move uniQure's Huntington's disease treatment closer to possible approval. Approval is not assured: the FDA may reject the data, uniQure must fund and complete a roughly 200-patient follow-up study, and any advisory meeting remains tentative.

QURE · uniQure N.V.

AI read · Good for QURE

The AI's read

Priority Review gives the application a target date for an FDA decision, and agreement on the follow-up study design gives uniQure a clearer next step. That study is planned to enroll about 200 patients. The treatment is still investigational, and the FDA may decide the available data do not support approval. uniQure also needs to fund and complete the follow-up study.

Get alerts for QURE

Follow uniQure N.V. (QURE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for QURE

Free on the App Store and Google Play, or on the web.